Issue 2, 2020

State-of-the-art iron-based nanozymes for biocatalytic tumor therapy

Abstract

Biocatalytic tumor therapy with artificial nanoscale enzyme-mimics (nanozymes) is an emerging strategy for the therapeutic intervention of a variety of malignant conditions, which can provide the combined benefits of enzyme-dependent biocatalytic activities and nanotechnology. Generally, these novel nanocatalysts employ particular multivalent ions as the catalytic center; they have demonstrated high catalytic efficiencies, due to which they are even more potent than natural enzymes, and they also exhibit better in vivo stability, functional versatility and lower manufacturing cost. It is well established that a malignant tumor has many enzymatic mutations, which provides ample opportunities for the development of biocatalytic tumor therapy with nanozymes. Most of the current research in this area revolves around iron-based nanostructures due to their easy manufacturing process, intrinsic biocompatibility, promising physical properties, and versatile and efficient catalytic activity. A great variety of studies in the recent decade have consistently demonstrated the translational potential of iron-based nanozymes for tumor therapy. Therefore, it would be of great practical significance to summarize the previous reports on the treatment-facilitative effects and tumor cell-damaging mechanisms of iron-based nanozymes, which primarily include tumor hypoxia amelioration, Fenton-enhanced ROS damage and the activation of the ferroptosis pathway. Additionally, we also discuss the critical issues that may affect their clinical translation and future development. We hope that these iron-based nanozymes can overcome the limitations of conventional therapies and open new avenues for tumor treatment.

Graphical abstract: State-of-the-art iron-based nanozymes for biocatalytic tumor therapy

Article information

Article type
Review Article
Submitted
02 Sept. 2019
Accepted
04 Nov. 2019
First published
05 Nov. 2019

Nanoscale Horiz., 2020,5, 202-217

State-of-the-art iron-based nanozymes for biocatalytic tumor therapy

M. Li, H. Zhang, Y. Hou, X. Wang, C. Xue, W. Li, K. Cai, Y. Zhao and Z. Luo, Nanoscale Horiz., 2020, 5, 202 DOI: 10.1039/C9NH00577C

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements